A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

Start Date01 Nov 2025

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

ChiCTR2500106983

/ Not yet recruitingPhase 4IIT

Exploratory Study of Rezvilutamide Combined with ADT as Neoadjuvant Therapy for Patients with Locally Advanced Prostate Cancer

Start Date01 Jul 2025

Sponsor / Collaborator-

ChiCTR2400093262

/ Not yet recruitingPhase 4IIT

An open-label, parallel-cohort, multicenter clinical study of Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer

Start Date01 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Rezvilutamide

100 Translational Medicine associated with Rezvilutamide

100 Patents (Medical) associated with Rezvilutamide

Literatures (Medical) associated with Rezvilutamide

01 Sep 2025·Journal of Pharmaceutical Analysis

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance

Review

Author: Wang, Jie ; Cho, William C ; Yu, Qingxin ; Wusiman, Dilinaer ; Xiong, Wei ; Tuo, Zhouting ; Ye, Luxia ; Koh, Siang Boon ; Shao, Fanglin ; Feng, Dechao ; Huang, Jianlin ; Wang, Zhipeng ; Li, Dengxiong ; Wu, Ruicheng

Prostate cancer is the most prevalent malignant tumor among men, ranking first in incidence and second in mortality globally. Novel hormone therapies (NHT) targeting the androgen receptor (AR) pathway have become the standard of care for metastatic prostate cancer. This review offers a comprehensive overview of NHT, including abiraterone, enzalutamide, apalutamide, darolutamide, and rezvilutamide, which have demonstrated efficacy in delaying disease progression and improving patient survival and quality of life. Nevertheless, resistance to NHT remains a critical challenge. The mechanisms underlying resistance are complex, involving AR gene amplification, mutations, splice variants, increased intratumoral androgens, and AR-independent pathways such as the glucocorticoid receptor, neuroendocrine differentiation, DNA repair defects, autophagy, immune evasion, and activation of alternative signaling pathways. This review discusses these resistance mechanisms and examines strategies to counteract them, including sequential treatment with novel AR-targeted drugs, chemotherapy, poly ADP-ribose polymerase inhibitors, radionuclide therapy, bipolar androgen therapy, and approaches targeting specific resistance pathways. Future research should prioritize elucidating the molecular basis of NHT resistance, optimizing existing therapeutic strategies, and developing more effective combination regimens. Additionally, advanced sequencing technologies and resistance research models should be leveraged to identify novel therapeutic targets and improve drug delivery efficiencies. These advancements hold the potential to overcome NHT resistance and significantly enhance the management and prognosis of patients with advanced prostate cancer.

01 Jul 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists

Article

Author: Qin, Yiyang ; Hou, Tingjun ; Zhang, Minkui ; Yuan, Leer ; Sheng, Rong ; Li, Dan ; Cai, Lvtao ; Liao, Jianing ; Liao, Jinbiao

Androgen receptor (AR) antagonists are the first-line medicine for the treatment of prostate cancer (PCa) in clinic. In our previous work, the tetrahydroquinoline derivative AT2 was identified as a novel scaffold AR antagonist via virtual screening and structural modifications, while its poor pharmacokinetic properties hindered further development. Herein, we report the systematic structural optimizations of AT2 and discover a novel tetrahydroquinoline derivative C2 as potent AR antagonist with an IC₅₀ value of 0.019 μM, accompanied with excellent selectivity over other nuclear receptors (PR, GR, MR). Further biological assays revealed that C2 significantly inhibited LNCaP cell proliferation, and efficiently reduced PSA protein expression. Especially, C2 showed superior efficacy against AR^F877L/T878A mutants compared to darolutamide and enzalutamide. Furthermore, C2 demonstrated excellent oral bioavailability, indicating the potential to enhance in vivo efficacy and to serve as a promising therapeutic option for PCa treatment.

01 Apr 2025·Translational Andrology and Urology

Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with low-volume, metastatic hormone-sensitive prostate cancer: a retrospective multicenter study

Article

Author: Wang, Xiaotian ; Wang, Baojun ; Chen, Yifan ; Wang, Liping ; Zhang, Qifu ; Mao, Lijun ; Li, Jun ; Zhang, Xu ; Xia, Dan ; He, Ting ; Sun, Fanghu ; Niu, Shaoxi ; Zhang, Jun ; Wang, Hui ; Wang, Jiangping ; Liu, Yugang ; Qiang, Ziyang ; Chen, Peijie ; Cai, Zheng ; Jin, Xin ; Lin, Chaoyu ; Wang, Du ; Xiang, Xuebao ; Zeng, Tao ; Ying, Zhou ; Ruan, Yashi

Background:

The CHART study established the combination of rezvilutamide and androgen deprivation therapy (ADT) as a standard treatment for patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). However, the therapeutic outcomes of this regimen in patients with low-volume mHSPC remain insufficiently defined. This study thus aimed to assess the real-world effectiveness of rezvilutamide combined with ADT in the treatment of low-volume mHSPC.

Methods:

This multicenter, noninterventional, observational study was conducted in China and included adult patients diagnosed with low-volume mHSPC who were treated with rezvilutamide in combination with ADT as determined by the investigator. The study assessed prostate-specific antigen (PSA) responses at multiple time points (3, 6, 9, and 12 months), including a PSA decline ≥50% (PSA50), a PSA decline ≥90% (PSA90), and a PSA level <0.2 ng/mL (undetectable PSA). Subgroup analyses of PSA responses were conducted according to baseline characteristics, including age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Gleason score.

Results:

Between August 29, 2023 and December 31, 2024, a total of 257 patients were enrolled in the study. The median age was 73 years [interquartile range (IQR), 68-77 years], and the median baseline PSA level was 38 ng/mL (IQR, 7-100 ng/mL). PSA responses were observed as early as 3 months after initiating rezvilutamide treatment, with 88% [176/199; 95% exact confidence interval (CI): 83-93%] achieving PSA50, 75% (149/199; 95% exact CI: 68-81%) achieving PSA90, and 54% (108/199; 95% exact CI: 47-61%) achieving undetectable PSA levels. These responses further improved at subsequent time points (6, 9, and 12 months). By 12 months, 100% (12/12; 95% exact CI: 74-100%) achieved PSA50, 92% (11/12; 95% exact CI: 62-100%) achieved PSA90, and 83% (10/12; 95% exact CI: 52-98%) had undetectable PSA levels.

Conclusions:

This study is the first to evaluate the effectiveness of rezvilutamide in patients with low-volume mHSPC. In a real-world clinical setting, the combination of rezvilutamide and ADT demonstrated favorable PSA response in this patient population. These findings provide additional treatment options for patients with low-volume mHSPC and support the need for further large-scale research on rezvilutamide in this subgroup.

News (Medical) associated with Rezvilutamide

20 Oct 2025

·www.prnewswire.com

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 studies across 14 innovative therapeutic programs, including nine oral presentations, two mini oral sessions, and four late-breaking abstracts (LBAs), underscoring its global R&D strength. These data highlight the company's commitment to multi-cancer coverage and multi-mechanism innovation in oncology. In parallel, Hengrui scheduled a series of academic events, fostering in-depth dialogue with leading global experts and clinical researchers on cutting-edge topics in oncology. These initiatives established a dynamic platform for international academic exchange and infused Chinese innovation into the global landscape of cancer diagnosis and treatment – marking a new chapter in Hengrui's journey of international scientific engagement. As one of the world's premier oncology platforms, the ESMO Annual Congress attracts more than ten thousand experts and hundreds of leading international pharmaceutical companies each year. The meeting showcases the latest advances in cancer research and therapeutics, serving as a high-level hub for academic exchange and collaboration. It continues to catalyze innovation and clinical translation across the oncology community, aligning with the 2025 Congress vision: "Standing by those who care about cancer." Global Vision: China Innovation Going Global At the ESMO 2025 Annual Congress, Hengrui co-hosted the roundtable "China Innovation Going Global," bringing together leading Chinese and international experts to discuss strategic pathways and future prospects for the globalization of China-origin innovations. During the global launch of the CARES-009 study, featuring Hengrui's innovative therapeutic combination of camrelizumab and rivoceranib, Academician Jia Fan of the Chinese Academy of Sciences and Professor Jian Zhou of Zhongshan Hospital, Fudan University, jointly presented the latest global data from the study, garnering widespread attention from the international oncology community. Ms. Jo Feng, President and Chief Operating Officer of Hengrui Pharma, led the company's delegation at this year's Congress. She stated, "ESMO serves as a premier global platform for oncology exchange, and this year, Hengrui proudly presented 46 research achievements – highlighting our growing academic presence on the world stage. As an innovation-driven global pharmaceutical company, Hengrui places medical innovation at the heart of its strategic vision, with a steadfast commitment to addressing unmet clinical needs. Looking ahead, we remain firmly patient-centric, continuing to advance groundbreaking therapies to improve the lives of patients worldwide." Breakthroughs Across Multiple Cancer Types At this year's ESMO Annual Congress, Hengrui had 46 oncology research projects accepted, including four LBAs, spanning 14 innovative therapeutic programs. Among these, nine were selected for oral presentations, two for mini oral sessions, 32 as posters, and three as e-posters. Collectively, these studies encompass more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, pancreatic cancer, lung cancer, sarcoma, biliary tract cancer, head and neck squamous cell carcinoma, prostate cancer, and thyroid cancer. In breast cancer, Hengrui had 11 research studies accepted, comprising one oral presentation, one mini oral, eight posters, and one e-poster. Notably, an LBA featuring Hengrui's antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) compared with pyrotinib plus capecitabine for patients with HER2-positive advanced or metastatic breast cancer was selected for presentation. Multiple studies highlighting both established and emerging therapies, including pyrotinib, dalpiciclib, and adebrelimab, demonstrate Hengrui's deep and sustained commitment to advancing breast cancer research. In gastrointestinal cancers, 14 studies were accepted, including two oral presentations, 11 posters, and one e-poster. Alongside flagship therapies such as camrelizumab and rivoceranib, four studies on adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in advancing care for patients with gastrointestinal malignancies. In lung cancer, six poster presentations featuring camrelizumab and adebrelimab were accepted, underscoring Hengrui's expanding footprint in this therapeutic area. These studies covered both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), further validating the clinical potential and versatility of these regimens. Across additional disease areas, including gynecologic tumors, thymic epithelial tumors, head and neck squamous cell carcinoma, sarcoma, prostate cancer, and thyroid cancer, Hengrui had 13 studies accepted, featuring a diverse range of innovative therapies such as camrelizumab, fuzuloparib, rivoceranib, rezvilutamide, adebrelimab, famitinib, HRS-7058, and HRS-4642. These included six oral presentations, one mini oral, five posters, and one e-poster, highlighting Hengrui's robust and broad-based R&D capabilities. In addition, two posters were accepted on hetrombopag and ondansetron oral soluble films, focusing on the prevention and management of chemotherapy-induced thrombocytopenia, nausea, and vomiting. Dr. Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, stated: "At this year's ESMO Annual Congress, we unveiled a broader and more impactful portfolio of research findings. The concentrated release of these breakthrough data not only reflects Hengrui's robust R&D capabilities, but also highlights the results of our science-driven, globally oriented innovation R&D strategy. Our pipeline is both deep and forward-looking – while reinforcing our existing product portfolio, we are also actively expanding into cutting-edge therapeutic areas. We firmly believe that through this in-depth engagement with the global oncology community, we can better enable our breakthroughs to benefit more patients worldwide." A Decade of ESMO Participation: China Innovation Going Global Since 2016, Hengrui Oncology has participated in the ESMO Annual Congress for 10 consecutive years, consistently setting new benchmarks for Chinese pharmaceutical companies. Between 2023 and 2025, Hengrui presented a total of 119 research achievements: 2023: 36 studies accepted, including two preferred oral presentations, six mini oral presentations, and 28 posters, covering multiple therapeutic areas such as gastrointestinal cancers, breast cancer, cervical cancer, pancreatic cancer, and melanoma. 2024: 37 studies accepted, spanning 13 innovative therapies and more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, and lung cancer. 2025: Marking its first-ever exhibition booth at ESMO, Hengrui presented 46 studies across 14 innovative medicines. This milestone represents a significant step forward in Hengrui's internationalization strategy and its commitment to advancing global cancer care. Commitment to Global Impact with the Promise of Patient Focus Hengrui remains steadfast in its commitment to science and innovation driven by the goal of addressing unmet patient needs. Leveraging a global R&D network, the company is advancing innovative medicines onto the international stage. Through a strategically structured pipeline, continuous breakthroughs across multiple cancer types, and active participation in global academic exchange, Hengrui Oncology is accelerating the internationalization and bringing new hope and broader treatment options to patients worldwide. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Hengrui Oncology Hengrui Oncology specializes in the development, production, and global commercialization of innovative cancer therapies. It is the first business unit within Hengrui to achieve technological breakthroughs and successfully enter international markets. Hengrui Oncology has established a robust and diversified oncology pipeline encompassing multiple tumor types, with a comprehensive portfolio that includes immunotherapies, targeted therapies, and ADCs. In key areas such as breast cancer, Hengrui Oncology provides full-course treatment solutions that span multiple lines of therapy. To date, 14 novel oncology agents developed by Hengrui have been approved for marketing in China. SOURCE Hengrui Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCOImmunotherapyDrug Approval

14 Nov 2023

·synapse.patsnap.com

What are androgen receptor inhibitors and how do you quickly get the latest development progress?

AR, or Androgen Receptor, plays a crucial role in the human body. It is a protein found in cells that binds to androgens, such as testosterone and dihydrotestosterone. Once bound, AR regulates gene expression, leading to the development and maintenance of male sexual characteristics. Additionally, AR is involved in various physiological processes, including bone and muscle growth, hair growth, and the regulation of mood and cognition. Dysregulation of AR activity can contribute to several diseases, including prostate cancer and androgen insensitivity syndrome. Understanding the role of AR is essential for developing targeted therapies and improving patient outcomes in the pharmaceutical industry. The androgen receptor (AR) signaling pathway plays a crucial role in all stages of the development and progression of prostate cancer. The ligament (dihydrotestosterone) binds to the AR, inducing its activation and entry into the nucleus. Within the cell nucleus, the AR binds to the androgen response element (ARE), acting as a transcriptional activator, promoting tumor cell proliferation and invasion, among other biological functions. Androgen deprivation therapy (ADT), which targets the AR, has become the fundamental treatment for late-stage prostate cancer. Moreover, the formation process of some splice isoforms of AR (e.g., AR-V7) results in incomplete AR proteins. Due to the absence of the LBD functional domain for ligament binding, these proteins can retain activation independent of androgens. This abnormal transcriptional regulation can lead to the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC) after ADT, becoming a bottleneck stage in the treatment of advanced prostate cancer. Interestingly, the AR signaling pathway not only plays a key role in male reproductive malignancies but also plays a significant role in other malignant tumors such as bladder cancer and breast cancer. The occurrence, progression, prognosis and drug treatment response of these tumors show clear gender differences, the mechanism of which is unclear. How do they work?AR inhibitors, also known as androgen receptor inhibitorsare a type of medication that block the activity of theandrogen receptor. The androgen receptor is a proteinfound in cells that binds to androgen hormones, such astestosterone and dihydrotestosterone (DHT). By inhibitingthe androgen receptor, AR inhibitors can interfere with thesignaling pathway that is activated by androgens. In the context of biomedicine, AR inhibitors are primarilyused in the treatment of hormone-dependent cancers,particularly prostate cancer. Prostate cancer cells oftenrely on androgen signaling for their growth and survivalBy blocking the androgen receptor, AR inhibitors cansuppress the growth of prostate cancer cells and slowdown the progression of the disease. AR inhibitors can be classified into different types basedon their mechanism of action. Some AR inhibitors directlycompete with androgens for binding to the androgenreceptor, while others prevent the androgen receptor fromtranslocating into the nucleus of the cell or interacting withcoactivator proteins. Examples ofAR inhibitors includeenzalutamide,bicalutamide. and abiraterone acetate. lt is important to note that AR inhibitors are prescribed andused under medical supervision, as they can have sideeffects and interactions with other medications. Commonside effects may include fatique, hot flashes, decreasedlibido, and gastrointestinal disturbances. Additionally,ARinhibitors are generally not recommended for use inwomen, as they can interfere with normal hormonalfunction. List of androgen receptor InhibitorsThe currently marketed androgen receptor inhibitors include: RezvilutamideProxalutamideClascoteroneDarolutamideDrospirenoneApalutamidePrasteroneTestosterone UndecanoateEnzalutamideDrospirenone/EstetrolFor more information, please click on the image below. What are androgen receptor inhibitors used for?Androgen receptor inhibitors can use to several diseases, including prostate cancer and androgen insensitivity syndrome. For more information, please click on the image below to log in and search. How to obtain the latest development progress of androgen receptor inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of androgen receptor inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

10 Aug 2023

·www.pharmaceutical-technology.com

Palisade Bio terminates its post-surgical abdominal adhesions treatment trial

Phalguni Deswal @Phalguni_GD Tranexamic acid is also under development for post-operative ileus, and accelerating the return of bowel function post-abdominal surgery. Image Credit: Buravleva stock / Shutterstock. Palisade Bio has terminated the development of its lead clinical candidate, tranexamic acid (LB1148), for reducing intra-abdominal adhesions in patients after elective bowel resection surgery. The news led to a sharp 69% decline in Palisade’s stock at market open on 9 August, compared to market close on the previous day. The company’s market cap stands at $4.8m. Recommended Reports Reports LOA and PTSR Model - Rezvilutamide in Liver Failure (Hepatic Insufficiency) GlobalData Reports LOA and PTSR Model - Aramchol in Liver Failure (Hepatic Insufficiency) GlobalData View all Companies Intelligence Palisade Bio, Inc Palisade Corp View all Tranexamic acid is a broad-spectrum serum protease inhibitor . It reduces damage to the intestine by neutralising digestive enzymes. The drug was investigated for the indication in a randomised, placebo-controlled, multicentre Phase II clinical trial (NCT02836470) that failed to meet its primary endpoint. Furthermore, 16 serious adverse events were observed in the tranexamic acid group, compared to 14 events in the placebo group, as per the press release . The clinical trial was wrought with difficulties. It was paused in July 2020 due to Covid-19, leading to low patient recruitment. After its restart in May 2022, the study’s protocol was changed to investigate the use of LB1148 in reducing adhesions from its original indication of the return of gastrointestinal function in patients post-elective bowel resection surgery. Tranexamic acid is also under development for post-operative ileus and accelerating the return of bowel function post-abdominal surgery . Palisade has a development and licencing agreement with Newsora for the tranexamic acid programme in China. The agreement grants Palisade clinical, regulatory, and commercial milestone-based payments, as well as tiered royalty payments for net annual sales in greater China. Palisade reduced its workforce by 30% at the start of 2023, as part of a cost-reduction strategy. As per the company’s 2022 financial report , it has cash reserves of $12.4m to fund its operation to mid-2024.

Phase 2Financial Statement

100 Deals associated with Rezvilutamide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rezvilutamide	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Castration-sensitive prostate cancer	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	28 Jun 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone-dependent prostate cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Dec 2025
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	20 Nov 2025
Prostatic Cancer	Phase 3	-	Luzsana Biotechnology, Inc.	18 May 2022
Locally Advanced Prostate Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Nov 2021
Prostate Cancer, Hereditary, 7	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Nov 2021
Castration-Resistant Prostatic Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	28 Jun 2018
Salivary duct carcinoma	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	10 Oct 2024
Adenocarcinoma of prostate	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	26 Nov 2020
Metastatic castration-resistant prostate cancer	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	19 Mar 2019
Chemical and Drug Induced Liver Injury	Phase 1	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	03 Feb 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03520478 (CHART, ESMO2025)	Phase 3	Hormone-dependent prostate cancer	520	Rezvilutamide+ADT	gqghnyquwc(uykfcxtdpq) = qxzmdqbmvl jktffrxfsm (ambgjnedrg ) View more	Positive	17 Oct 2025
				Bicalutamide+ADT	gqghnyquwc(uykfcxtdpq) = ivhmbgawfu jktffrxfsm (ambgjnedrg ) View more
NCT05753566 (ESMO2025)	Phase 2	Non-metastatic prostate cancer	45	Rezvilutamide + ADT	zmjawzleqg(ezbiisvtaz) = lcftkxodha uxfbbmpnga (idvmibwpma ) View more	Positive	17 Oct 2025
NCT03520478 (CHART, Pubmed \| Med)	Phase 3	Hormone-dependent prostate cancer prostate-specific antigen	654	Rezvilutamide plus ADT	gcwfdcfuvr(cgbhhrwdec) = cxjkjeohum igbxnomlln (qzbmhqlcvt ) View more	Positive	01 Feb 2025
				Bicalutamide plus ADT	gcwfdcfuvr(cgbhhrwdec) = tjteenddsz igbxnomlln (qzbmhqlcvt ) View more
NCT03520478 (CHART, Pubmed \| NEWS) Manual	Phase 3	Hormone-dependent prostate cancer \| Metastatic castration-resistant prostate cancer	-	rezvilutamide + ADT	fmzhbhdrsi(gxtcassdna) = lvyuygxzde dwnqfturnl (mathnyvqin, 7.4 - 16.6) View more	Superior	18 Dec 2024
				bicalutamide + ADT	fmzhbhdrsi(gxtcassdna) = tfmdbpjdeq dwnqfturnl (mathnyvqin, 5.5 - 8.3) View more
NCT03520478 (CHART, ESMO_ASIA2024) Manual	Phase 3	Castration-sensitive prostate cancer	654	Rezvilutamide + ADT (≤64 years)	lvdfoayntg(japjoflubj): HR = 0.83 (95% CI, 0.48 - 1.44) View more	Positive	09 Dec 2024
				Bicalutamide + ADT (≤64 years)
NCT05924256 (ASCO2024) Manual	Phase 2	Salivary Gland Neoplasms HER2 Negative \| ERBB2 Amplification \| HER2 Overexpression \| ... View more	21	SHR-A1811(anti-HER2) 4.8 mg/kg	vungyyxsxx(yxfplkfzsz) = tzeelunuqh qzgiamwmpt (evtwpwokpx ) View more	Positive	24 May 2024
				rezvilutamide 24leuprolided plus leuprolide 3.75mg s.c.	vungyyxsxx(yxfplkfzsz) = rznyprgryk qzgiamwmpt (evtwpwokpx ) View more
NCT04603833 (ASCO2024)	Phase 2	Metastatic castration-resistant prostate cancer	36	Rezvilutamide 160 mg plus Docetaxel	mnjohbntqe(gqfejluqmx) = iamjgorllp teavqzzigq (gxjofyvvrp ) View more	Positive	24 May 2024
				Rezvilutamide 240 mg plus Docetaxel	mnjohbntqe(gqfejluqmx) = mjhzfnnvud teavqzzigq (gxjofyvvrp ) View more
NCT03520478 (CHART, ESMO 12023 \| ESMO 22023) Manual	Phase 3	Metastatic castration-resistant prostate cancer PSA	654	Rezvilutamide + ADT (deep PSA decline)	-	Positive	22 Oct 2023
				Bicalutamide + ADT (deep PSA decline)
NCT03520478 (CHART, Pubmed) Manual	Phase 3	Castration-Resistant Prostatic Cancer	654	ADT+Rezvilutamide	kiwnaxaxez(epnyerorto) = dscmgmozyd otigfyydct (lzvekkeuni, NR - NR) View more	Superior	05 Sep 2022
				ADT+Bicalutamide	kiwnaxaxez(epnyerorto) = utxoufxanp otigfyydct (lzvekkeuni, 15.7 - NR) View more
NCT03520478 (CHART, ASCO2022)	Phase 3	Castration-Resistant Prostatic Cancer	654	SHR3680	tcifkuopnr(veytphrqfi): HR = 0.58 (95% CI, 0.42 - 0.8), P-Value = 0.0009 View more	Positive	02 Jun 2022
				Bicalutamide

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rezvilutamide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation